>유럽 간질성 방광염 시장, 심각도(경미한 ~ 중간 및 중간 ~ 심각한), 치료 유형(약물, 방광 주입, 보툴리눔 독소 A, 신경 자극 및 수술 ), 투여 경로(경구, 비경구, 방광 내, 국소 및 기타), 구매 방식( 처방전 없이 구입 가능한 약물 및 처방약), 환자 유형(소아 및 성인), 최종 사용자(병원, 진료소, 가정 의료 및 기타), 유통 채널(직접 입찰, 소매 판매 및 기타) - 업계 동향 및 2029년까지의 예측.
유럽 간질성 방광염 시장 분석 및 규모
간질성 방광염(IC)이라고 하는 방광 통증 상태의 한 형태는 원인을 알 수 없는 방광과 골반저에 지속적인 통증을 유발합니다. 여성 비뇨기과적 지속적 골반 불편 증후군이라고 합니다. 즉시 자주 소변을 보아야 한다는 느낌이 증상입니다. 삶의 질 저하와 우울증은 IC/BPS와 관련이 있습니다. 영향을 받는 사람들 중 다수는 섬유근육통과 과민성 대장 증후군을 겪기도 합니다.
유럽 간질성 방광염 시장은 2022년부터 2029년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2022년부터 2029년까지의 예측 기간 동안 9.7%의 CAGR로 성장하고 있으며 2029년까지 5억 5,619만 달러에 도달할 것으로 예상한다고 분석합니다.
|
보고서 메트릭 |
세부 |
|
예측 기간 |
2022년부터 2029년까지 |
|
기준 연도 |
2021 |
|
역사적 연도 |
2020 (2019-2014로 사용자 정의 가능) |
|
양적 단위 |
수익 (단위: USD 백만) |
|
다루는 세그먼트 |
심각도(경미~중간 및 중간~중증), 치료 유형(약물, 방광 주입, 보툴리눔 독소 A, 신경 자극 및 수술 ), 투여 경로(경구, 비경구, 방광 내, 국소 및 기타), 구매 방식( 처방전 없이 구입 가능한 약물 및 처방약), 환자 유형(소아 및 성인), 최종 사용자(병원, 진료소, 가정 의료 및 기타), 유통 채널(직접 입찰, 소매 판매 및 기타) |
|
적용 국가 |
독일, 영국, 프랑스, 이탈리아, 스페인, 터키, 러시아, 네덜란드, 스위스, 벨기에, 그리고 유럽의 다른 나라들. |
|
시장 참여자 포함 |
Alvogen, Janssen Pharmaceuticals, Inc., Sandoz AG, Sun Pharmaceutical Industries Ltd., Accord Healthcare US, Avet Pharmaceuticals Inc., Lannett, Viatris Inc., Pfizer, Inc., Strides Pharma Science Limited, GSK plc. Prestige Consumer Healthcare Inc., Amneal Pharmaceuticals LLC, Zydus Pharmaceuticals, Inc., Apotex Inc., Aurobindo Pharma USA, VistaPharm, Inc., Dr. Reddy's Laboratories, Inc., Teva Pharmaceuticals USA, Inc., Bayer AG, Reckitt Benckiser Group PLC 등이 있습니다. |
시장 정의
A persistent illness known as interstitial cystitis causes bladder pressure, bladder pain and pelvic pain. Mild discomfort to severe agony is all possible levels of pain. The disorder belongs to a group of illnesses called painful bladder syndrome. Different tests are performed by doctors to diagnose the painful bladder disorder, which include X-rays, urine tests and a bladder wall examination using a cystoscope. It is characterized by pain, pressure, or discomfort perceived to be related to the urinary bladder that lasts more than six months with at least one other urinary symptom, such as frequency or persistent urge. These bladder disorders cause inflammation in the bladder, which is generally called cystitis. Treatment of the disorder depends on the cause of the problem. It may include medication and surgery in severe cases.
Interstitial Cystitis Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail as below:
Drivers
-
INCREASED PREVALENCE OF INTERSTITIAL CYSTITIS (IC)
The disorder known as interstitial cystitis (IC), also known as bladder discomfort syndrome, is chronic or long-lasting and it produces uncomfortable urine symptoms. Individuals with IC may experience varied symptoms. For example, some persons experience little pressure, pain, or discomfort in the pelvic region. Others may battle with severe bladder pain, urinary urgency—the sudden need to urinate—or frequency—the desire to urinate more frequently. One of the main factors influencing the growth rate of the interstitial cystitis market is the increasing prevalence of interstitial cystitis nowadays. Women are particularly affected by this condition. Common side effects include allergies, fibromyalgia and endometriosis. Urinary frequency, urgency and pelvic pain are clinical symptoms of interstitial cystitis, which can occur both during the day and at night.
-
RISE IN HEALTHCARE EXPENDITURE
The cost of healthcare has climbed globally as people's disposable income has increased in different countries. Additionally, government agencies and healthcare providers are taking the initiative by increasing healthcare spending in order to meet population needs.
For instance,
-
As per December 2020, World Health Organization (WHO) report stated that global healthcare expenditure was rising in 2018, which was USD 8.3 trillion, which is around 10% of GDP (USD1.080 per citizen) compared to USD 7.6 trillion in 2016. Moreover, global health spending grew by 3.9 percent between 2000 and 2017.
Growing healthcare expenditure is also benefiting further economic growth and healthcare sector growth. It is primarily helpful as it significantly affects the development of better and advanced medical products in the market. Thereby surge in healthcare expenditure is expected to act as a driver for the Europe interstitial cystitis market.
Opportunities
-
IMPROVING HEALTHCARE SYSTEM
Interstitial cystitis or bladder pain syndrome is a chronic pelvic pain syndrome related to the urinary bladder. It is characterized by pain, pressure, or discomfort perceived to be related to the urinary bladder that lasts more than six months with at least one other urinary symptom, such as frequency or persistent urge. Thus, improvement in one or more symptoms of bladder pain can be particularly effective in improving residual urine and bladder hyperextension.
As a result of rising infectious diseases worldwide, it is required to build a better healthcare system for the diagnosis of various infections in underdeveloped regions. Improving healthcare systems in underdeveloped regions can fuel market growth over the forecast period.
These awareness programs helped people understand the correct treatment at an appropriate time. This increasing awareness allows the consumers to select novel treatments as per age and it is efficacy, which enhances the sales of different types of products. Thus, improving a better healthcare system is expected to act as an opportunity for Europe interstitial cystitis market growth in the forecasted period.
Restraints/Challenges
However, the barriers to interstitial cystitis treatment techniques and the high cost of the treatment process in some regions may impede the growth of interstitial cystitis treatment hampering the market growth. Additionally, high competition in medical technology industries and long lead time for the overseas qualification can be challenging factors for the growth of the market.
This interstitial cystitis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the lung cancer surgery market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you to make an informed market decision to achieve market growth.
Recent Development
- In July 2020, UCB and Ferring Pharmaceuticals Inc. announced they had entered into a co-promotion agreement to commercialize the prefilled syringe formulation of CIMZIA used for interstitial cystitis.
- In April 2021, Kyorin Pharmaceutical Co., Ltd., a wholly owned subsidiary of KYORIN Holdings, Inc., launched Interstitial cystitis “Zymso Intravesical Solution 50 %.
Europe Interstitial Cystitis Market Scope
The Europe interstitial cystitis market is segmented into severity, treatment type, route of administration, mode of purchase, patient type, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Severity
- Mild To Moderate
- Moderate To Severe
On the basis of severity, the Europe interstitial cystitis market is segmented into mild to moderate and moderate to severe.
Treatment Type
- Medications
- Bladder Instillation
- Botulinum Toxin A
- Nerve Stimulation
- Surgery
On the basis of treatment type, the Europe interstitial cystitis market is segmented into medications, bladder instillation, botulinum toxin A, nerve stimulation and surgery.
Route of Administration
- Oral
- Parenteral
- Intravesical
- Topical
- Others
On the basis of route of administration, the Europe interstitial cystitis market is segmented into oral, parenteral, intravesical, topical and others.
Mode of Purchase
- Over the counter
- Prescription
On the basis of mode of purchase, the Europe interstitial cystitis market is segmented into over the counter and prescription.
Patient Type
- Pediatric
- Adults
On the basis of patient type, the Europe interstitial cystitis market is segmented into paediatric and adults.
End User
- Hospitals
- Clinics
- Home Healthcare
- Others
On the basis of end user, the Europe interstitial cystitis market is segmented into hospitals, clinics, home healthcare and others.
Distribution Channel
- Direct tender
- Retail sales
- Others
On the basis of distribution channels, the Europe interstitial cystitis market is segmented into direct tender, retail sales and others.
Interstitial Cystitis Market Regional Analysis/Insights
The interstitial cystitis market is analyzed, and market size insights and trends are provided by country, severity, treatment type, route of administration, mode of purchase, patient type, end user, and distribution channel, as referenced above.
The interstitial cystitis market comprises of the countries Germany, U.K., France, Italy, Spain, Turkey, Russia, Netherlands, Switzerland, Belgium and Rest of Europe.
Germany dominates the Europe interstitial cystitis market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the rising need for the verification and validation of interstitial cystitis treatment processes in the region, and rapid research development is boosting the market.
보고서의 국가 섹션은 또한 현재 및 미래 시장 추세에 영향을 미치는 개별 시장 영향 요인과 시장 규정의 변화를 제공합니다. 신규 및 교체 판매, 국가 인구 통계, 질병 역학 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 글로벌 브랜드의 존재 및 가용성과 국내 및 국내 브랜드와의 치열한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
경쟁 환경 및 간질성 방광염 시장 점유율 분석
간질성 방광염 시장 경쟁 구도는 경쟁자에 대한 세부 정보를 제공합니다. 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 프로그램 우위가 포함됩니다. 위의 데이터 포인트는 간질성 방광염 시장에 대한 회사의 초점에만 관련이 있습니다.
간질성 방광염 시장에서 활동하는 주요 기업으로는 Alvogen, Janssen Pharmaceuticals, Inc., Sandoz AG, Sun Pharmaceutical Industries Ltd, Accord Healthcare US, Avet Pharmaceuticals Inc., Lannett, Viatris Inc., Pfizer, Inc., Strides Pharma Science Limited, GSK plc. Prestige Consumer Healthcare Inc., Amneal Pharmaceuticals LLC, Zydus Pharmaceuticals , Inc., Apotex Inc., Aurobindo Pharma USA, VistaPharm, Inc., Dr. Reddy's Laboratories, Inc., Teva Pharmaceuticals USA, Inc., Bayer AG, Reckitt Benckiser Group PLC 등이 있습니다.
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석되고 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 유럽 대 지역 및 공급업체 점유율 분석이 포함됩니다. 추가 문의 사항이 있는 경우 분석가에게 전화를 요청하십시오.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE INTERSTITIAL CYSTITIS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES
4.3 PIPELINE ANALYSIS FOR INTERSTITIAL CYSTITIS TREATMENT MARKET
4.4 EPIDEMIOLOGY
5 EUROPE INTERSTITIAL CYSTITIS MARKET: REGULATIONS
5.1 FOOD AND DRUG ADMINISTRATION (FDA) GUIDELINES
5.2 EUROPEAN MEDICINES AGENCY (EMA) GUIDELINES
5.3 JAPAN REGULATORY GUIDANCE
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASED PREVALENCE OF INTERSTITIAL CYSTITIS (IC)
6.1.2 RISE IN HEALTHCARE EXPENDITURE
6.1.3 STRATEGIC INITIATIVES OF KEY PLAYERS
6.1.4 INCREASE IN R&D EFFORTS IN THE HEALTHCARE INDUSTRY
6.1.5 RISING DISEASE MANAGEMENT PROGRAMS
6.2 RESTRAINTS
6.2.1 HIGH COST OF TREATMENT OF INTERSTITIAL CYSTITIS
6.2.2 LACK OF AWARENESS ABOUT BLADDER DISORDERS-RELATED PROBLEMS
6.2.3 DEARTH OF SKILLED PROFESSIONALS
6.3 OPPORTUNITIES
6.3.1 FAVORABLE REIMBURSEMENT SCENARIO
6.3.2 INCREASE IN DRUG APPROVALS AND LAUNCHES
6.3.3 IMPROVING HEALTHCARE SYSTEM
6.3.4 COMBINATION OF DIFFERENT TARGET THERAPIES
6.4 CHALLENGES
6.4.1 STRINGENT GOVERNMENT REGULATIONS ON NEW PRODUCTS APPROVAL
6.4.2 PATENT EXPIRY OF DRUGS
7 EUROPE INTERSTITIAL CYSTITIS MARKET, BY SEVERITY
7.1 OVERVIEW
7.2 MILD TO MODERATE
7.3 MODERATE TO SEVERE
8 EUROPE INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE
8.1 OVERVIEW
8.2 MEDICATIONS
8.2.1 ANALGESICS
8.2.1.1 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
8.2.1.1.1 IBUPROFEN
8.2.1.1.2 NAPROXEN
8.2.1.1.3 OTHERS
8.2.1.2 ACETAMINOPHEN
8.2.1.3 NON-NARCOTIC PAIN MEDICATION
8.2.1.3.1 METHENAMINE
8.2.1.3.2 PHENAZOPYRIDINE
8.2.1.3.3 OTHERS
8.2.1.4 NARCOTIC PAIN MEDICATION
8.2.1.4.1 CODEINE
8.2.1.4.2 HYDROCODONE
8.2.1.4.3 OXYCODONE
8.2.1.4.4 OXYMORPHONE
8.2.1.4.5 MORPHINE
8.2.1.4.6 HYDROMORPHONE
8.2.1.4.7 METHADONE
8.2.1.4.8 OTHERS
8.2.2 ANTIHISTAMINES
8.2.2.1 LORATADINE
8.2.2.2 HYDROXYZINE
8.2.2.3 OTHERS
8.2.3 TRICYCLIC ANTIDEPRESSANTS
8.2.3.1 AMITRIPTYLINE
8.2.3.2 IMIPRAMINE
8.2.3.3 OTHERS
8.2.4 IMMUNOSUPPRESSANTS
8.2.4.1 CYCLOSPORINE
8.2.4.2 MYCOPHENOLATE
8.2.4.3 OTHERS
8.2.5 PENTOSAN POLYSULFATE SODIUM
8.2.6 OTHERS
8.2.6.1 ALPHA BLOCKERS
8.2.6.1.1 DOXAZOSIN
8.2.6.1.2 TERAZOSIN
8.2.6.1.3 TAMSULOSIN
8.2.6.1.4 OTHERS
8.2.6.2 AMPHETAMINES
8.2.6.3 LEUKOTRIENE INHIBITORS
8.2.6.3.1 MONTELUKAST
8.2.6.3.2 ZAFIRLUKAST
8.2.6.3.3 OTHERS
8.2.6.4 OTHERS
8.3 BLADDER INSTILLATIONS
8.3.1 DIMETHYL SULFOXIDE
8.3.2 HEPARIN
8.3.3 OTHERS
8.4 BOTULINUM TOXIN A
8.5 SURGERY
8.5.1 FULGURATION
8.5.2 RESECTION
8.5.3 BLADDER AUGMENTATION
8.6 NERVE STIMULATIONS
9 EUROPE INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION
9.1 OVERVIEW
9.2 ORAL
9.2.1 TABLETS
9.2.1.1 EXTENDED RELEASE
9.2.1.2 IMMEDIATE RELEASE
9.2.2 CAPSULES
9.2.3 OTHERS
9.3 PARENTERAL
9.4 INTRAVESICAL
9.5 TOPICAL
9.6 OTHERS
10 EUROPE INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE
10.1 OVERVIEW
10.2 OVER THE COUNTER
10.3 PRESCRIPTION
11 EUROPE INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE
11.1 OVERVIEW
11.2 ADULTS
11.3 PEDIATRIC
12 EUROPE INTERSTITIAL CYSTITIS MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.3 CLINICS
12.4 HOME HEALTHCARE
12.5 OTHERS
13 EUROPE INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
13.3.1 PHARMACY STORES
13.3.2 ONLINE RETAIL CHANNEL
13.3.3 OTHERS
13.4 OTHERS
14 EUROPE INTERSTITIAL CYSTITIS MARKET, BY GEOGRAPHY
14.1 EUROPE
14.1.1 GERMANY
14.1.2 U.K.
14.1.3 FRANCE
14.1.4 ITALY
14.1.5 SPAIN
14.1.6 TURKEY
14.1.7 RUSSIA
14.1.8 NETHERLANDS
14.1.9 SWITZERLAND
14.1.10 BELGIUM
14.1.11 REST OF EUROPE
15 EUROPE INTERSTITIAL CYSTITIS MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: EUROPE
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 TEVA PHARMACEUTICALS INDUSTRIES LTD.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 PRODUCT PORTFOLIO
17.1.4 RECENT DEVELOPMENTS
17.2 SANDOZ AG (A SUBSIDIARY OF NOVARTIS AG)
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 HIKMA PHARMACEUTICALS PLC
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.4 DR. REDDY'S LABORATORIES LTD
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 BAYER AG
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENT
17.6 AMNEAL PHARMACEUTICAL LLC.
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENTS
17.7 APOTEX
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENT
17.8 AUROBINDO PHARMA USA
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 AVET PHARMACEUTICALS INC.
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 ALVOGEN
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 10.3RECENT DEVELOPMENT
17.11 ACCORD-UK LTD
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 11.3RECENT DEVELOPMENT
17.12 GLAXOSMITHKLINE PLC
17.12.1 COMPANY SNAPSHOT
17.12.2 12.2REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENT
17.13 JOHNSON & JOHNSON SERVICES, INC.
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
17.14 LANNETT
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENT
17.15 PRESTIGE CONSUMER HEALTHCARE
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENTS
17.16 PFIZER INC.
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
17.17 RECKITT BENCKISER GROUP PLC.
17.17.1 COMPANY SNAPSHOT
17.17.2 REVENUE ANALYSIS
17.17.3 PRODUCT PORTFOLIO
17.17.4 RECENT DEVELOPMENT
17.18 SUN PHARMACEUTICAL INDUSTRIES LTD.
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENT
17.19 STRIDES PHARMA SCIENCE LIMITED.
17.19.1 COMPANY SNAPSHOT
17.19.2 REVENUE ANALYSIS
17.19.3 PRODUCT PORTFOLIO
17.19.4 RECENT DEVELOPMENT
17.2 VIATRIS INC.
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENT
17.21 VISTA PHARM INC.
17.21.1 COMPANY SNAPSHOT
17.21.2 PRODUCT PORTFOLIO
17.21.3 RECENT DEVELOPMENTS
17.22 ZYDUS PHARMACEUTICALS INC.,
17.22.1 COMPANY SNAPSHOT
17.22.2 REVENUE ANALYSIS
17.22.3 PRODUCT PORTFOLIO
17.22.4 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
표 목록
TABLE 1 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED
TABLE 2 EUROPE INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 3 EUROPE MILD TO MODERATE IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 EUROPE MODERATE TO SEVERE IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 EUROPE INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 6 EUROPE MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 EUROPE MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 8 EUROPE ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 9 EUROPE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 10 EUROPE NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 11 EUROPE NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 12 EUROPE ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 13 EUROPE TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 EUROPE IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 EUROPE OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 EUROPE ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 EUROPE LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 18 EUROPE BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 20 EUROPE BOTULINUM TOXIN A IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 EUROPE SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 EUROPE SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 23 EUROPE NERVE STIMULATIONS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 EUROPE INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 25 EUROPE ORAL IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 EUROPE ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 27 EUROPE TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 28 EUROPE PARENTERAL IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 EUROPE INTRAVESICAL IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 EUROPE TOPICAL IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 EUROPE OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 EUROPE INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 33 EUROPE OVER THE COUNTER IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 EUROPE PRESCRIPTION IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 EUROPE INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 36 EUROPE ADULTS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 EUROPE PEDIATRIC IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 EUROPE INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 39 EUROPE HOSPITALS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 EUROPE CLINICS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 EUROPE HOME HEALTHCARE IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 42 EUROPE OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 43 EUROPE INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 44 EUROPE DIRECT TENDER IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 45 EUROPE RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 46 EUROPE RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 47 EUROPE OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 48 EUROPE INTERSTITIAL CYSTITIS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 49 EUROPE INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 50 EUROPE INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 51 EUROPE MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 52 EUROPE ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 53 EUROPE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 EUROPE NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 EUROPE NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 56 EUROPE ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 57 EUROPE IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 58 EUROPE TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 59 EUROPE OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 60 EUROPE ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 61 EUROPE LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 62 EUROPE BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 63 EUROPE SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 EUROPE INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 65 EUROPE ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 66 EUROPE TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 67 EUROPE INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 68 EUROPE INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 69 EUROPE INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 70 EUROPE INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 71 EUROPE RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 72 GERMANY INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 73 GERMANY INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 74 GERMANY MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 75 GERMANY CELL ANALYZERS IN FLOW CYTOMETRY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 76 GERMANY ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 77 GERMANY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 78 GERMANY NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 GERMANY NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 GERMANY ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 81 GERMANY IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 GERMANY TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 83 GERMANY OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 84 GERMANY ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 85 GERMANY LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 86 GERMANY BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 87 GERMANY SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 88 GERMANY INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 89 GERMANY ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 90 GERMANY TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 91 GERMANY INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 92 GERMANY INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 93 GERMANY INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 94 GERMANY INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 95 GERMANY RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 96 U.K. INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 97 U.K. INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 98 U.K. MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 99 U.K. ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 100 U.K. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 101 U.K. NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 102 U.K. NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 103 U.K. ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 104 U.K. IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 105 U.K. TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 106 U.K. OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 107 U.K. ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 108 U.K. LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 109 U.K. BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 110 U.K. SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 111 U.K. INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 112 U.K. ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 113 U.K. TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 114 U.K. INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 115 U.K. INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 116 U.K. INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 117 U.K. INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 118 U.K. RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 119 FRANCE INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 120 FRANCE INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 121 FRANCE MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 122 FRANCE ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 123 FRANCE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 124 FRANCE NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 125 FRANCE NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 126 FRANCE ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 127 FRANCE IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 128 FRANCE TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 129 FRANCE OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 130 FRANCE ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 131 FRANCE LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 132 FRANCE BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 133 FRANCE SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 134 FRANCE INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 135 FRANCE ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 136 FRANCE TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 137 FRANCE INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 138 FRANCE INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 139 FRANCE INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 140 FRANCE INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 141 FRANCE RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 142 ITALY INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 143 ITALY INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 144 ITALY MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 145 ITALY ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 146 ITALY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 147 ITALY NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 148 ITALY NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 149 ITALY ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 150 ITALY IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 151 ITALY TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 152 ITALY OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 153 ITALY ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 154 ITALY LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 155 ITALY BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 156 ITALY SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 157 ITALY INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 158 ITALY ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 159 ITALY TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 160 ITALY INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 161 ITALY INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 162 ITALY INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 163 ITALY INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 164 ITALY RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 165 SPAIN INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 166 SPAIN INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 167 SPAIN MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 168 SPAIN ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 169 SPAIN NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 170 SPAIN NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 171 SPAIN NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 172 SPAIN ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 173 SPAIN IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 174 SPAIN TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 175 SPAIN OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 176 SPAIN ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 177 SPAIN LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 178 SPAIN BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 179 SPAIN SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 180 SPAIN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 181 SPAIN ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 182 SPAIN TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 183 SPAIN INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 184 SPAIN INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 185 SPAIN INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 186 SPAIN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 187 SPAIN RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 188 TURKEY INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 189 TURKEY INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 190 TURKEY MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 191 TURKEY ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 192 TURKEY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 193 TURKEY NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 194 TURKEY NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 195 TURKEY ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 196 TURKEY IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 197 TURKEY TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 198 TURKEY OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 199 TURKEY ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 200 TURKEY LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 201 TURKEY BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 202 TURKEY SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 203 TURKEY INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 204 TURKEY ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 205 TURKEY TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 206 TURKEY INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 207 TURKEY INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 208 TURKEY INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 209 TURKEY INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 210 TURKEY RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 211 RUSSIA INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 212 RUSSIA INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 213 RUSSIA MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 214 RUSSIA ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 215 RUSSIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 216 RUSSIA NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 217 RUSSIA NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 218 RUSSIA ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 219 RUSSIA IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 220 RUSSIA TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 221 RUSSIA OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 222 RUSSIA ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 223 RUSSIA LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 224 RUSSIA BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 225 RUSSIA SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 226 RUSSIA INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 227 RUSSIA ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 228 RUSSIA TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 229 RUSSIA INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 230 RUSSIA INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 231 RUSSIA INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 232 RUSSIA INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 233 RUSSIA RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 234 NETHERLANDS INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 235 NETHERLANDS INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 236 NETHERLANDS MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 237 NETHERLANDS ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 238 NETHERLANDS NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 239 NETHERLANDS NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 240 NETHERLANDS NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 241 NETHERLANDS ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 242 NETHERLANDS IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 243 NETHERLANDS TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 244 NETHERLANDS OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 245 NETHERLANDS ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 246 NETHERLANDS LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 247 NETHERLANDS BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 248 NETHERLANDS SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 249 NETHERLANDS INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 250 NETHERLANDS ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 251 NETHERLANDS TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 252 NETHERLANDS INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 253 NETHERLANDS INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 254 NETHERLANDS INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 255 NETHERLANDS INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 256 NETHERLANDS RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 257 SWITZERLAND INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 258 SWITZERLAND INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 259 SWITZERLAND MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 260 SWITZERLAND ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 261 SWITZERLAND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 262 SWITZERLAND NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 263 SWITZERLAND NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 264 SWITZERLAND ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 265 SWITZERLAND IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 266 SWITZERLAND TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 267 SWITZERLAND OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 268 SWITZERLAND ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 269 SWITZERLAND LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 270 SWITZERLAND BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 271 SWITZERLAND SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 272 SWITZERLAND INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 273 SWITZERLAND ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 274 SWITZERLAND TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 275 SWITZERLAND INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 276 SWITZERLAND INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 277 SWITZERLAND INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 278 SWITZERLAND INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 279 SWITZERLAND RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 280 BELGIUM INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 281 BELGIUM INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 282 BELGIUM MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 283 BELGIUM ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 284 BELGIUM NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 285 BELGIUM NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 286 BELGIUM NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 287 BELGIUM ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 288 BELGIUM IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 289 BELGIUM TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 290 BELGIUM OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 291 BELGIUM ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 292 BELGIUM LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 293 BELGIUM BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 294 BELGIUM SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 295 BELGIUM INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 296 BELGIUM ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 297 BELGIUM TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 298 BELGIUM INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 299 BELGIUM INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 300 BELGIUM INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 301 BELGIUM INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 302 BELGIUM RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 303 REST OF EUROPE INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
그림 목록
FIGURE 1 EUROPE INTERSTITIAL CYSTITIS MARKET: SEGMENTATION
FIGURE 2 EUROPE INTERSTITIAL CYSTITIS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE BLADDER DISORDERS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE INTERSTITIAL CYSTITIS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE INTERSTITIAL CYSTITIS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE INTERSTITIAL CYSTITIS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE INTERSTITIAL CYSTITIS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE INTERSTITIAL CYSTITIS MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 EUROPE INTERSTITIAL CYSTITIS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE INTERSTITIAL CYSTITIS MARKET: SEGMENTATION
FIGURE 11 RISING EPIDEMIC AND PANDEMIC OUTBREAK AND INCREASING PREVALENCE OF INTERSTITIAL CYSTITIS IS EXPECTED TO DRIVE THE EUROPE INTERSTITIAL CYSTITIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 MILD TO MODERATE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE INTERSTITIAL CYSTITIS MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE INTERSTITIAL CYSTITIS MARKET
FIGURE 14 EUROPE INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, 2021
FIGURE 15 EUROPE INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, 2022-2029 (USD MILLION)
FIGURE 16 EUROPE INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, CAGR (2022-2029)
FIGURE 17 EUROPE INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, LIFELINE CURVE
FIGURE 18 EUROPE INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, 2021
FIGURE 19 EUROPE INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, 2022-2029 (USD MILLION)
FIGURE 20 EUROPE INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, CAGR (2022-2029)
FIGURE 21 EUROPE INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 22 EUROPE INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 23 EUROPE INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
FIGURE 24 EUROPE INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 25 EUROPE INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 26 EUROPE INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, 2021
FIGURE 27 EUROPE INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
FIGURE 28 EUROPE INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, CAGR (2022-2029)
FIGURE 29 EUROPE INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, LIFELINE CURVE
FIGURE 30 EUROPE INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, 2021
FIGURE 31 EUROPE INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, 2022-2029 (USD MILLION)
FIGURE 32 EUROPE INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, CAGR (2022-2029)
FIGURE 33 EUROPE INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 34 EUROPE INTERSTITIAL CYSTITIS MARKET: BY END USER, 2021
FIGURE 35 EUROPE INTERSTITIAL CYSTITIS MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 36 EUROPE INTERSTITIAL CYSTITIS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 37 EUROPE INTERSTITIAL CYSTITIS MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 EUROPE INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 39 EUROPE INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 40 EUROPE INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 41 EUROPE INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 EUROPE INTERSTITIAL CYSTITIS MARKET: SNAPSHOT (2021)
FIGURE 43 EUROPE INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2021)
FIGURE 44 EUROPE INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 45 EUROPE INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 46 EUROPE INTERSTITIAL CYSTITIS MARKET: BY SEVERITY (2022-2029)
FIGURE 47 EUROPE INTERSTITIAL CYSTITIS MARKET: COMPANY SHARE 2021 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
